The in silico construction of a PDGFRβ kinase homology model and ensuing medicinal chemistry guided by molecular modeling, led to the identification of potent, small molecule inhibitors of PDGFR. Subsequent exploration of structure-activity relationships (SAR) led to the incorporation of a constrained secondary amine to enhance selectivity. Further refinements led to the integration of a fluorine substituted piperidine, which resulted in significant reduction of P-glycoprotein (Pgp) mediated efflux and improved bioavailability. Compound 28 displayed oral exposure in rodents and had a pronounced effect in a pharmacokinetic-pharmacodynamic (PKPD) assay.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027622PMC
http://dx.doi.org/10.1021/ml4003953DOI Listing

Publication Analysis

Top Keywords

discovery novel
4
novel class
4
class imidazo[12-a]pyridines
4
imidazo[12-a]pyridines potent
4
potent pdgfr
4
pdgfr activity
4
activity oral
4
oral bioavailability
4
bioavailability silico
4
silico construction
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!